44.22  1.05 (2.43%)		11-11 15:52
Open: 43.55 High: 44.3 Volume: 658,774		Pre. Close: 43.17 Low: 43.51 Market Cap: 9,588(M)

Short term
Mid term
Targets	6-month :	54.9	1-year :	57.92
Resists	First :	47	Second :	49.59
Pivot price	46.12
Supports	First :	42.81	Second :	35.62
MAs	MA(5) :	43.6	MA(20) :	46.64
	MA(100) :	47.5	MA(250) :	44.61
MACD	MACD :	-1	Signal :	-0.5
%K %D	K(14,3) :	12.1	D(3) :	8.7
RSI	RSI(14): 38.3
52-week	High :	51.88	Low :	37.63

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ QGEN ] has closed above bottom band by 28.1%. Bollinger Bands are 128.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	43.75 - 44	44 - 44.19
Low:	42.26 - 42.6	42.6 - 42.89
Close:	42.66 - 43.17	43.17 - 43.59

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Tue, 11 Nov 2025
QIAGEN NV : Deutsche Bank reiterates its Buy rating - MarketScreener

Tue, 11 Nov 2025
Qiage announces $300M buyback plan - MSN

Mon, 10 Nov 2025
Qiagen N.V. Just Beat EPS By 30%: Here's What Analysts Think Will Happen Next - Yahoo Finance

Mon, 10 Nov 2025
Nuance Investments LLC Sells 1,420,510 Shares of Qiagen N.V. $QGEN - MarketBeat

Mon, 10 Nov 2025
QIAGEN (NYSE: QGEN) debuts QIAsymphony Connect; early access before mid-2026 release - Stock Titan

Mon, 10 Nov 2025
TD Cowen Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $48 - 富途牛牛

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	217 (M)
Shares Float	215 (M)
Held by Insiders	0.4 (%)
Held by Institutions	80.9 (%)
Shares Short	6,010 (K)
Shares Short P.Month	6,670 (K)

EPS	1.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	16.17
Profit Margin	18.2 %
Operating Margin	25.4 %
Return on Assets (ttm)	9 %
Return on Equity (ttm)	10.8 %
Qtrly Rev. Growth	7.5 %
Gross Profit (p.s.)	7.56
Sales Per Share	9.4
EBITDA (p.s.)	4.6
Qtrly Earnings Growth	0 %
Operating Cash Flow	675 (M)
Levered Free Cash Flow	683 (M)

PE Ratio	26.14
PEG Ratio	0
Price to Book value	2.73
Price to Sales	4.69
Price to Cash Flow	14.19

Dividend	0.25
Forward Dividend	0
Dividend Yield	0.5%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.